Scienture Holdings (SCNX) announced the official launch of commercial sales for Arbli\u2122 (losartan potassium) Oral Suspension, 10 mg\/mL<\/strong>, marking a major milestone for the company as it transitions from development to full-scale commercialization. Arbli\u2122 is the first FDA-approved, ready-to-use oral suspension formulation of losartan<\/strong>, offering a convenient and consistent treatment alternative for patients unable to take traditional solid dosage forms.<\/p>\n\n\n\n According to IQVIA data (MAT June 2025), the U.S. losartan market is valued at approximately $256 million annually<\/strong>, with over 71 million prescriptions written each year<\/strong>. Scienture sees this as a substantial market opportunity for Arbli\u2122, which is expected to address a critical unmet need among patients who require flexible dosing options \u2014 particularly pediatric, geriatric, and dysphagic populations.<\/p>\n\n\n\n To accelerate adoption, Scienture has launched a multi-channel promotional campaign<\/strong> targeting healthcare professionals (HCPs) and institutional buyers. The company has also finalized multiple PBM-led and GPO agreements<\/strong>, securing formulary access and expanding commercial reach to more than 2,500 healthcare institutions<\/strong> across the United States. These include hospitals, clinics, nursing homes, specialty pharmacies, and long-term care facilities, representing potential penetration into nearly 20% of the institutional market<\/strong>.<\/p>\n\n\n\n \u201cThe start of commercial sales for Arbli\u2122 represents a major achievement for Scienture as we move from innovation to execution,\u201d said Narasimhan Mani<\/strong>, President and co-CEO of Scienture. Executive Chairman and co-CEO Shankar Hariharan<\/strong> added, \u201cArbli\u2122 reflects our mission to deliver patient-focused pharmaceutical solutions that enhance accessibility and care. The early enthusiasm from healthcare providers underscores the strong market demand for this first-of-its-kind formulation.\u201d<\/p>\n\n\n\n With commercial sales now underway, Scienture aims to build long-term growth through expanded awareness, institutional partnerships, and patient-centered value creation.<\/p>\n\n\n\n